HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Renoprotective effects of direct renin inhibition in glomerulonephritis.

Abstract
The development of glomerulonephritis causes glomerular injury and renal dysfunction and is thought to increase renin release, thus activating the renin-angiotensin system (RAS). The aims of this study were to demonstrate activation of the intrarenal RAS and determine the effects of direct renin inhibition (DRI) on the progression of glomerulonephritis. Rats were treated with anti-Thy1.1 antibody with or without DRI, aliskiren (30 mg/kg/d). In the glomerulonephritic rats, protein, microalbumin excretion levels, urinary angiotensinogen excretion, glomerular expansion score and intrarenal transforming growth factor-β and plasminogen activator inhibitor-1 mRNA levels were augmented compared with control rats; however, hypertension was not observed in the glomerulonephritic rats, and aliskiren treatment did not modify their blood pressure. The increases in urinary protein (94.7 ± 13.0 mg/d) and microalbumin (7.52 ± 2.6 mg/d) excretion were reduced by aliskiren (43.6 ± 4.5 mg/d of protein and 2.57 ± 0.7 mg/d of microalbumin). Furthermore, the progression of glomerular expansion and elevation of intrarenal transforming growth factor-β and plasminogen activator inhibitor-1 levels were prevented by aliskiren. Importantly, aliskiren suppressed the augmentation of urinary angiotensinogen levels, the increased angiotensinogen expression in the kidneys and the increases in Ang II levels in renal medulla induced by the anti-Thy1.1 antibody. These results suggest that DRI with aliskiren prevents intrarenal RAS activation leading to mitigation of the development of glomerulonephritis. In addition, the renoprotective effects of DRI on glomerulonephritis occur in a blood pressure-independent manner. Accordingly, treatment with aliskiren may be an effective approach to treat glomerulonephritis and other intrarenal RAS-associated kidney diseases.
AuthorsKayoko Miyata, Ryousuke Satou, Daisuke Inui, Akemi Katsurada, Dale Seth, Allison Davis, Maki Urushihara, Hiroyuki Kobori, Kenneth D Mitchell, L Gabriel Navar
JournalThe American journal of the medical sciences (Am J Med Sci) Vol. 348 Issue 4 Pg. 306-14 (Oct 2014) ISSN: 1538-2990 [Electronic] United States
PMID24165783 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Amides
  • Fumarates
  • aliskiren
  • Renin
Topics
  • Amides (pharmacology, therapeutic use)
  • Animals
  • Fumarates (pharmacology, therapeutic use)
  • Glomerulonephritis (metabolism, prevention & control)
  • Kidney Glomerulus (drug effects, metabolism)
  • Male
  • Rats
  • Rats, Inbred F344
  • Rats, Sprague-Dawley
  • Renin (antagonists & inhibitors, metabolism)
  • Renin-Angiotensin System (drug effects, physiology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: